search
Back to results

Abuse Potential of Buprenorphine/Naloxone

Primary Purpose

Opioid-Related Disorders

Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Buprenorphine/naloxone
Sponsored by
National Institute on Drug Abuse (NIDA)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Opioid-Related Disorders

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Actively abusing illegal opioids Qualifies for opioid substitution treatment (e.g., methadone or buprenorphine), but not in active treatment at the time of study entry Meets DSM-IV criteria for opioid dependence Exclusion Criteria: Significant medical problems (e.g., insulin dependent diabetes mellitus) Non-substance use psychiatric disorders (e.g., schizophrenia) Seeking substance abuse treatment

Sites / Locations

  • Johns Hopkins University (BPRU) Bayview Campus

Outcomes

Primary Outcome Measures

Opiate withdrawal
opiate agonist symptoms
physiologic measures

Secondary Outcome Measures

Full Information

First Posted
September 6, 2005
Last Updated
January 11, 2017
Sponsor
National Institute on Drug Abuse (NIDA)
Collaborators
Johns Hopkins University
search

1. Study Identification

Unique Protocol Identification Number
NCT00149539
Brief Title
Abuse Potential of Buprenorphine/Naloxone
Official Title
Abuse Potential of Buprenorphine/Naloxone as a Function of Maintenance Dose of Buprenorphine/Naloxone
Study Type
Interventional

2. Study Status

Record Verification Date
July 2007
Overall Recruitment Status
Terminated
Why Stopped
Funding ended for the study
Study Start Date
June 2004 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
January 2006 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
National Institute on Drug Abuse (NIDA)
Collaborators
Johns Hopkins University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Buprenorphine is a treatment for opioid dependence. Naloxone is given in addition to buprenorphine in order to limit the abuse potential that is commonly associated with buprenorphine. The purpose of this study is to determine the abuse potential of high doses of buprenorphine/naloxone in opioid dependent individuals.
Detailed Description
Buprenorphine, a mixed agonist-antagonist opioid (or partial agonist), is a safe and effective treatment for opioid dependence. However, there is concern that buprenorphine may be abused due to its high abuse potential. A sublingual buprenorphine/naloxone combination tablet may reduce the risk of abuse associated with buprenorphine alone. The purpose of this study is to determine the abuse potential of acute doses of buprenorphine/naloxone in individuals who are maintained on different daily doses of sublingual buprenorphine/naloxone. Participants will be maintained on both low and high doses of buprenorphine/naloxone. They will be challenged with low- and high-dose injected buprenorphine/naloxone, as well as active and placebo controls at each maintenance dose. During study visits, physiologic, subjective, and psychomotor responses to challenge sessions will be monitored and compared to known pharmacologic effects of opioid drugs.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Opioid-Related Disorders

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
Double
Allocation
Randomized
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Buprenorphine/naloxone
Primary Outcome Measure Information:
Title
Opiate withdrawal
Time Frame
up to one day
Title
opiate agonist symptoms
Time Frame
up to one day
Title
physiologic measures
Time Frame
up to one day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Actively abusing illegal opioids Qualifies for opioid substitution treatment (e.g., methadone or buprenorphine), but not in active treatment at the time of study entry Meets DSM-IV criteria for opioid dependence Exclusion Criteria: Significant medical problems (e.g., insulin dependent diabetes mellitus) Non-substance use psychiatric disorders (e.g., schizophrenia) Seeking substance abuse treatment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eric C. Strain, MD
Organizational Affiliation
Johns Hopkins University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Johns Hopkins University (BPRU) Bayview Campus
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21224 6823
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Abuse Potential of Buprenorphine/Naloxone

We'll reach out to this number within 24 hrs